These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20228816)

  • 21. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
    McMillin DW; Delmore J; Negri J; Ooi M; Klippel S; Miduturu CV; Gray NS; Richardson PG; Anderson KC; Kung AL; Mitsiades CS
    PLoS One; 2011; 6(7):e20226. PubMed ID: 21750699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
    Weisberg E; Liu Q; Zhang X; Nelson E; Sattler M; Liu F; Nicolais M; Zhang J; Mitsiades C; Smith RW; Stone R; Galinsky I; Nonami A; Griffin JD; Gray N
    PLoS One; 2013; 8(2):e56473. PubMed ID: 23437141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.
    Poeschinger T; Renner A; Weber T; Scheuer W
    Mol Imaging Biol; 2013 Feb; 15(1):28-39. PubMed ID: 22528864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Luminescence applications for chemotherapeutic drug development.
    Andreotti PE; Caceres G; Zamkina R; Dauphinée M
    Recent Results Cancer Res; 2003; 161():3-12. PubMed ID: 12528794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.
    Coleman SJ; Watt J; Arumugam P; Solaini L; Carapuca E; Ghallab M; Grose RP; Kocher HM
    World J Gastroenterol; 2014 Jul; 20(26):8471-81. PubMed ID: 25024603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
    Kitano H; Kitadai Y; Teishima J; Yuge R; Shinmei S; Goto K; Inoue S; Hayashi T; Sentani K; Yasui W; Matsubara A
    Cancer Med; 2017 Oct; 6(10):2308-2320. PubMed ID: 28834289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation.
    Zhao H; Tang C; Cui K; Ang BT; Wong ST
    J Neurosurg; 2009 Aug; 111(2):238-46. PubMed ID: 19199503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis.
    Niu G; Zhu L; Ho DN; Zhang F; Gao H; Quan Q; Hida N; Ozawa T; Liu G; Chen X
    Theranostics; 2013; 3(3):190-200. PubMed ID: 23471295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells.
    Kuo CH; Lu YC; Tseng YS; Shi CS; Chen SH; Chen PT; Wu FL; Chang YP; Lee YR
    Breast Cancer; 2014 May; 21(3):358-69. PubMed ID: 22926505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
    Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
    Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
    Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
    Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs.
    Campana D; Manabe A; Evans WE
    Leukemia; 1993 Mar; 7(3):482-8. PubMed ID: 7680404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional drug screening assay reveals potential glioma therapeutics.
    Badr CE; Wurdinger T; Tannous BA
    Assay Drug Dev Technol; 2011 Jun; 9(3):281-9. PubMed ID: 21184646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive bioluminescent and microPET imaging for the regulation of NF-kappaB in human hepatoma-bearing mice.
    Chang TJ; Chang YJ; Ho TY; Hsiang CY; Yu CY; Lee TW; Lin WJ; Chang CH
    Anticancer Res; 2009 Apr; 29(4):987-94. PubMed ID: 19414336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
    Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
    Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.
    Jacamo R; Chen Y; Wang Z; Ma W; Zhang M; Spaeth EL; Wang Y; Battula VL; Mak PY; Schallmoser K; Ruvolo P; Schober WD; Shpall EJ; Nguyen MH; Strunk D; Bueso-Ramos CE; Konoplev S; Davis RE; Konopleva M; Andreeff M
    Blood; 2014 Apr; 123(17):2691-702. PubMed ID: 24599548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.